SOHO 2025 Annual Meeting

Sarah Profitt, PharmD, BCOP, reviews follow-up efficacy and safety from the phase III MANIFEST-2 trial, which evaluated the BET inhibitor pelabresib plus the JAK inhibitor ruxolitinib among patients with myelofibrosis (MF) who had not received prior JAK inhibitor therapy (Abstract MPN-794).

Sarah Profitt, PharmD, BCOP, discusses data from a matching adjusted indirect treatment comparison of pacritinib and momelotinib for patients with thrombocytopenic myelofibrosis (MF). The study authors found that pacritinib outperformed momelotinib in terms of symptom reduction, spleen volume reduction, red blood cell transfusion independence, and overall survival (Abstract MPN-752).

Sarah Profitt, PharmD, BCOP, talks about clinical outcomes seen with momelotinib compared to ruxolitinib in patients with myelofibrosis and moderate anemia; findings were generally consistent with the intention-to-treat population of the trial (Abstract MPN-690).